The solution structure and dynamics of full-length human cerebral dopamine neurotrophic factor and its neuroprotective role against α-synuclein oligomers

Journal of Biological Chemistry

Volumn 290, Issue 33, 2015, Pages 20527-20540

  Latge, Cristiane ^a   Cabral, Katia M S ^a   De Oliveira, Guilherme A P ^a   Raymundo, Diana P ^a   Freitas, Julia A ^a   Johanson, Laizes ^a   Romão, Luciana F ^a   Palhano, Fernando L ^a   Herrmann, Torsten ^b   Almeida, Marcius S ^a   Foguel, Debora ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b Institut des Sciences Analytiques   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMINES; DISEASES; NEURODEGENERATIVE DISEASES; NEURONS; NEUROPHYSIOLOGY; OLIGOMERS;

CONFORMATIONAL DYNAMICS; DOPAMINERGIC NEURONS; NEUROTROPHIC FACTORS; PHYSIOLOGICAL DAMAGES; PURIFICATION PROTOCOL; SOLUTION STRUCTURES; THREE-DIMENSIONAL CRYSTALS; THREE-DIMENSIONAL STRUCTURE;

CRYSTAL STRUCTURE;

ALPHA SYNUCLEIN; CEREBRAL DOPAMINE NEUROTROPHIC FACTOR; LACTATE DEHYDROGENASE; MESENCEPHALIC ASTROCYTE DERIVED NEUROTROPHIC FACTOR; NEUROTROPHIC FACTOR; UNCLASSIFIED DRUG; BIOPOLYMER; CDNF PROTEIN, HUMAN; NERVE GROWTH FACTOR; NEUROPROTECTIVE AGENT;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL DIFFERENTIATION; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DEGENERATIVE DISEASE; DOPAMINERGIC NERVE CELL; DRUG DETERMINATION; DRUG STRUCTURE; EMBRYO; ENZYME ACTIVE SITE; FEMALE; MOUSE; MTT ASSAY; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; ANIMAL; CELL LINE; CHEMISTRY; HUMAN; METABOLISM; NUCLEAR MAGNETIC RESONANCE; PHYSIOLOGY; PROTEIN CONFORMATION; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY;

ALPHA-SYNUCLEIN; ANIMALS; BIOPOLYMERS; CELL LINE; CRYSTALLOGRAPHY, X-RAY; HUMANS; MICE; NERVE GROWTH FACTORS; NEUROPROTECTIVE AGENTS; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; PROTEIN CONFORMATION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84939645793     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M115.662254     Document Type: Article

References (71)

1. Fahn, S. (2003) Description of Parkinson's disease as a clinical syndrome. Ann. N.Y. Acad. Sci. 991, 1-14
2. Baba, M., Nakajo, S., Tu, P. H., Tomita, T., Nakaya, K., Lee, V. M., Trojanowski, J. Q., and Iwatsubo, T. (1998) Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am. J. Pathol. 152, 879-884
3. Winner, B., Jappelli, R., Maji, S. K., Desplats, P. A., Boyer, L., Aigner, S., Hetzer, C., Loher, T., Vilar, M., Campioni, S., Tzitzilonis, C., Soragni, A., Jessberger, S., Mira, H., Consiglio, A., Pham, E., Masliah, E., Gage, F. H., and Riek, R. (2011) In vivo demonstration that α-synuclein oligomers are toxic. Proc. Natl. Acad. Sci. U.S.A. 108, 4194-4199
4. Lindsay, R. M., Altar, C. A., Cedarbaum, J. M., Hyman, C., and Wiegand, S. J. (1993) The therapeutic potential of neurotrophic factors in the treatment of Parkinson's disease. Exp. Neurol. 124, 103-118
5. Airavaara, M., Harvey, B. K., Voutilainen, M. H., Shen, H., Chou, J., Lindholm, P., Lindahl, M., Tuominen, R. K., Saarma, M., Hoffer, B., and Wang, Y. (2012) CDNF protects the nigrostriatal dopamine system and promotes recovery after MPTP treatment in mice. Cell Transplant. 21, 1213-1223
6. Voutilainen, M. H., Bäck, S., Peränen, J., Lindholm, P., Raasmaja, A., Männistö, P. T., Saarma, M., and Tuominen, R. K. (2011) Chronic infusion of CDNF prevents 6-OHDA-induced deficits in a rat model of Parkinson's disease. Exp. Neurol. 228, 99-108
7. Lindholm, P., Voutilainen, M. H., Laurén, J., Peränen, J., Leppänen, V.-M., Andressoo, J.-O., Lindahl, M., Janhunen, S., Kalkkinen, N., Timmusk, T., Tuominen, R. K., and Saarma, M. (2007) Novel neurotrophic factor CDNF protects and rescues midbrain dopamine neurons in vivo 2. Nature 448, 73-77
8. Nadella, R., Voutilainen, M. H., Saarma, M., Gonzalez-Barrios, J. A., Leon-Chavez, B. A., Jiménez, J. M., Jiménez, S. H., Escobedo, L., and Martinez-Fong, D. (2014) Transient transfection of human CDNF gene reduces the 6-hydroxydopamine-induced neuroinflammation in the rat substantia nigra. J. Neuroinflammation 11, 209
9. Bäck, S., Peränen, J., Galli, E., Pulkkila, P., Lonka-Nevalaita, L., Tamminen, T., Voutilainen, M. H., Raasmaja, A., Saarma, M., Männistö, P. T., and Tuominen, R. K. (2013) Gene therapy with AAV2-CDNF provides functional benefits in a rat model of Parkinson's disease. Brain Behav. 3, 75-88
10. Ren, X., Zhang, T., Gong, X., Hu, G., Ding, W., and Wang, X. (2013) AAV2-mediated striatum delivery of human CDNF prevents the deterioration of midbrain dopamine neurons in a 6-hydroxydopamine induced parkinsonian rat model. Exp. Neurol. 248, 148-156
11. Petrova, P., Raibekas, A., Pevsner, J., Vigo, N., Anafi, M., Moore, M. K., Peaire, A. E., Shridhar, V., Smith, D. I., Kelly, J., Durocher, Y., and Commissiong, J. W. (2003) MANF: a new mesencephalic, astrocyte-derived neurotrophic factor with selectivity for dopaminergic neurons. J. Mol. Neurosci. 20, 173-188
12. Palgi, M., Lindström, R., Peränen, J., Piepponen, T. P., Saarma, M., and Heino, T. I. (2009) Evidence that DmMANF is an invertebrate neurotrophic factor supporting dopaminergic neurons. Proc. Natl. Acad. Sci. U.S.A. 106, 2429-2434
13. Sun, Z.-P., Gong, L., Huang, S.-H., Geng, Z., Cheng, L., and Chen, Z.-Y. (2011) Intracellular trafficking and secretion of cerebral dopamine neurotrophic factor in neurosecretory cells. J. Neurochem. 117, 121-132
14. Parkash, V., Lindholm, P., Peränen, J., Kalkkinen, N., Oksanen, E., Saarma, M., Leppänen, V. M., and Goldman, A. (2009) The structure of the conserved neurotrophic factors MANF and CDNF explains why they are bifunctional. Protein Eng. Des. Sel. 22, 233-241
15. Hellman, M., Arumäe, U., Yu, L. Y., Lindholm, P., Peränen, J., Saarma, M., and Permi, P. (2011) Mesencephalic astrocyte-derived neurotrophic factor (MANF) has a unique mechanism to rescue apoptotic neurons. J. Biol. Chem. 286, 2675-2680
16. Hoseki, J., Sasakawa, H., Yamaguchi, Y., Maeda, M., Kubota, H., Kato, K., and Nagata, K. (2010) Solution structure and dynamics of mouse ARMET. FEBS Lett. 584, 1536-1542
17. Cohen, H. Y., Lavu, S., Bitterman, K. J., Hekking, B., Imahiyerobo, T. A., Miller, C., Frye, R., Ploegh, H., Kessler, B. M., and Sinclair, D. A. (2004) Acetylation of the C terminus of Ku70 by CBP and PCAF controls Bax-mediated apoptosis. Mol. Cell 13, 627-638
18. Mei, J.-M., and Niu, C.-S. (2014) Effects of CDNF on 6-OHDA-induced apoptosis in PC12 cells via modulation of Bcl-2/Bax and caspase-3 activation. Neurol. Sci. 35, 1275-1280
19. Henderson, M. J., Richie, C. T., Airavaara, M., Wang, Y., and Harvey, B. K. (2013) Mesencephalic astrocyte-derived neurotrophic factor (MANF) secretion and cell surface binding are modulated by KDEL receptors. J. Biol. Chem. 288, 4209-4225
20. Lindström, R., Lindholm, P., Kallijärvi, J., Yu, L.-Y., Piepponen, T. P., Arumäe, U., Saarma, M., and Heino, T. I. (2013) Characterization of the structural and functional determinants of MANF/CDNF in Drosophila in vivo model. PLoS ONE 8, e73928
21. Cordero-Llana, Ó., Houghton, B. C., Rinaldi, F., Taylor, H., Yáñez-Muñoz, R. J., Uney, J. B., Wong, L. F., and Caldwell, M. A. (2015) Enhanced efficacy of the CDNF/MANF family by combined intranigral overexpression in the 6-OHDA rat model of Parkinson's disease. Mol. Ther. 23, 244-254
22. Latgé, C., Cabral, K. M., Almeida, M. S., and Foguel, D. (2013) 1H-, 13C- and 15N-NMR assignment of the N-terminal domain of human cerebral dopamine neurotrophic factor (CDNF). Biomol. NMR Assign. 7, 101-103
23. Braga, C. A., Follmer, C., Palhano, F. L., Khattar, E., Freitas, M. S., Romão, L., Di Giovanni, S., Lashuel, H. A., Silva, J. L., and Foguel, D. (2011) The anti-Parkinsonian drug selegiline delays the nucleation phase of α-synuclein aggregation leading to the formation of nontoxic species. J. Mol. Biol. 405, 254-273
24. Bax, A. D., and Grzesiek, S. (1993) Methodological advances in protein NMR. Acc. Chem. Res. 26, 131-138
25. Guerry, P., and Herrmann, T. (2012) Comprehensive automation for NMR structure determination of proteins. Methods Mol. Biol. 831, 429-451
26. Serrano, P., Pedrini, B., Mohanty, B., Geralt, M., Herrmann, T., and Wüthrich, K. (2012) The J-UNIO protocol for automated protein structure determination by NMR in solution. J. Biomol. NMR 53, 341-354
27. Zhu, G., Xia, Y., Nicholson, L. K., and Sze, K. H. (2000) Protein dynamics measurements by TROSY-based NMR experiments. J. Magn. Reson. 143, 423-426
28. Renner, C., Schleicher, M., Moroder, L., and Holak, T. A. (2002) Practical aspects of the 2D 15N-[1H]-NOE experiment. J. Biomol. NMR 23, 23-33
29. Meiboom, S., and Gill, D. (1958) Modified spin-echo method for measuring nuclear relaxation times. Rev. Sci. Instrum. 29, 688-691
30. Vold, R. L., Waugh, J. S., Klein, M. P., and Phelps, D. E. (1968) Measurement of spin relaxation in complex systems. J. Chem. Phys. 48, 3831-3832
31. Peng, J. W., and Wagner, G. (1994) Investigation of protein motions via relaxation measurements. Methods Enzymol. 239, 563-596
32. Nederveen, A. J., Doreleijers, J. F., Vranken, W., Miller, Z., Spronk, C. A., Nabuurs, S. B., Güntert, P., Livny, M., Markley, J. L., Nilges, M., Ulrich, E. L., Kaptein, R., and Bonvin, A. M. (2005) RECOORD: a recalculated coordinate database of 500+ proteins from the PDB using restraints from the BioMagResBank. Proteins 59, 662-672
33. Brunger, A. T. (2007) Version 1.2 of the Crystallography and NMR system. Nat. Protoc. 2, 2728-2733
34. Spera, S., and Bax, A. (1991) Empirical correlation between protein backbone conformation and C.α and C.β 13C nuclear magnetic resonance chemical shifts. J. Am. Chem. Soc. 113, 5490-5492
35. Luginbühl, P., Szyperski, T., and Wüthrich, K. (1995) Statistical basis for the use of 13Cα chemical shifts in protein structure determination. J. Magn. Reson. B 109, 229-233
36. Lin, D., Manning, N. O., Jiang, J., Abola, E. E., Stampf, D., Prilusky, J., and Sussman, J. L. (2000) AutoDep: a web-based system for deposition and validation of macromolecular structural information. Acta Crystallogr. D Biol. Crystallogr. 56, 828-841
37. Koradi, R., Billeter, M., and Wüthrich, K. (1996) MOLMOL: a program for display and analysis of macromolecular structures. J. Mol. Graph. 14, 51-55, 29-32
38. Svergun, D. I. (1999) Restoring low resolution structure of biological macromolecules from solution scattering using simulated annealing. Biophys. J. 76, 2879-2886
39. Volkov, V. V., and Svergun, D. I. (2003) Uniqueness of ab initio shape determination in small-angle scattering. J. Appl. Cryst. 36, 860-864
40. Kozin, M. B., and Svergun, D. I. (2001) Automated matching of high- and low-resolution structural models. J. Appl. Cryst. 34, 33-41
41. Krüger, R., Kuhn, W., Müller, T., Woitalla, D., Graeber, M., Kösel, S., Przuntek, H., Epplen, J. T., Schöls, L., and Riess, O. (1998) Ala30Pro mutation in the gene encoding α-synuclein in Parkinson's disease. Nat. Genet. 18, 106-108
42. Shaltiel-Karyo, R., Frenkel-Pinter, M., Rockenstein, E., Patrick, C., Levy-Sakin, M., Schiller, A., Egoz-Matia, N., Masliah, E., Segal, D., and Gazit, E. (2013) A blood-brain barrier (BBB) disrupter is also a potent α-synuclein (α-syn) aggregation inhibitor: a novel dual mechanism of mannitol for the treatment of Parkinson disease (PD). J. Biol. Chem. 288, 17579-17588
43. LeVine, H., 3rd (1993) Thioflavine T interaction with synthetic Alzheimer's disease β-amyloid peptides: detection of amyloid aggregation in solution. Protein Sci. 2, 404-410
44. Romão, L. F., Sousa Vde, O., Neto, V. M., and Gomes, F. C. (2008) Glutamate activates GFAP gene promoter from cultured astrocytes through TGF-β1 pathways. J. Neurochem. 106, 746-756
45. Mosmann, T. (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65, 55-63
46. Laemmli, U. K. (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227, 680-685
47. Jarymowycz, V. A., and Stone, M. J. (2006) Fast time scale dynamics of protein backbones: NMR relaxation methods, applications, and functional consequences. Chem. Rev. 106, 1624-1671
48. Boehr, D. D., and Wright, P. E. (2008) How do proteins interact? Science 320, 1429-1430
49. Csermely, P., Palotai, R., and Nussinov, R. (2010) Induced fit, conformational selection and independent dynamic segments: an extended view of binding events. Trends Biochem. Sci. 35, 539-546
50. Sawada, M., Hayes, P., and Matsuyama, S. (2003) Cytoprotective membrane-permeable peptides designed from the Bax-binding domain of Ku70. Nat. Cell. Biol. 5, 352-357
51. Iwai, A., Masliah, E., Yoshimoto, M., Ge, N., Flanagan, L., de Silva, H. A., Kittel, A., and Saitoh, T. (1995) The precursor protein of non-Aβ component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system. Neuron 14, 467-475
52. Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., Stenroos, E. S., Chandrasekharappa, S., Athanassiadou, A., Papapetropoulos, T., Johnson, W. G., Lazzarini, A. M., Duvoisin, R. C., Di Iorio, G., Golbe, L. I., and Nussbaum, R. L. (1997) Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science 276, 2045-2047
53. Narhi, L., Wood, S. J., Steavenson, S., Jiang, Y., Wu, G. M., Anafi, D., Kaufman, S. A., Martin, F., Sitney, K., Denis, P., Louis, J. C., Wypych, J., Biere, A. L., and Citron, M. (1999) Both familial Parkinson's disease mutations accelerate α-synuclein aggregation. J. Biol. Chem. 274, 9843-9846
54. van Rooijen, B. D., van Leijenhorst-Groener, K. A., Claessens, M. M., and Subramaniam, V. (2009) Tryptophan fluorescence reveals structural features of α-synuclein oligomers. J. Mol. Biol. 394, 826-833
55. Wan, O. W., and Chung, K. K. (2012) The role of alpha-synuclein oligomerization and aggregation in cellular and animal models of Parkinson's disease. PLoS ONE 7, e38545 10.1371/journal.pone.0038545
56. Smeyne, R. J., and Jackson-Lewis, V. (2005) The MPTP model of Parkinson's disease. Mol. Brain Res. 134, 57-66
57. Fraichard, A., Chassande, O., Bilbaut, G., Dehay, C., Savatier, P., and Samarut, J. (1995) In vitro differentiation of embryonic stem cells into glial cells and functional neurons. J. Cell Sci. 108, 3181-3188
58. Bruhn, H. (2005) A short guided tour through functional and structural features of saposin-like proteins. Biochem. J. 389, 249-257
59. Chakrabarti, P., and Janin, J. (2002) Dissecting protein-protein recognition sites. Proteins 47, 334-343
60. Bordner, A. J., and Abagyan, R. (2005) Statistical analysis and prediction of protein-protein interfaces. Proteins 60, 353-366
61. De, S., Krishnadev, O., Srinivasan, N., and Rekha, N. (2005) Interaction preferences across protein-protein interfaces of obligatory and non-obligatory components are different. BMC Struct. Biol. 5, 15
62. Lashuel, H. A., Overk, C. R., Oueslati, A., and Masliah, E. (2013) The many faces of α-synuclein: from structure and toxicity to therapeutic target. Nat. Rev. Neurosci. 14, 38-48
63. Conway, K. A., Rochet, J. C., Bieganski, R. M., and Lansbury, P. T., Jr. (2001) Kinetic stabilization of the α-synuclein protofibril by a dopamine-α-synuclein adduct. Science 294, 1346-1349
64. Webb, J. L., Ravikumar, B., Atkins, J., Skepper, J. N., and Rubinsztein, D. C. (2003) α-Synuclein is degraded by both autophagy and the proteasome. J. Biol. Chem. 278, 25009-25013
65. Spencer, B., Potkar, R., Trejo, M., Rockenstein, E., Patrick, C., Gindi, R., Adame, A., Wyss-Coray, T., and Masliah, E. (2009) Beclin 1 gene transfer activates autophagy and ameliorates the neurodegenerative pathology in α-synuclein models of Parkinson's and Lewy body diseases. J. Neurosci. 29, 13578-13588
66. Decressac, M., Mattsson, B., Weikop, P., Lundblad, M., Jakobsson, J., and Björklund, A. (2013) TFEB-mediated autophagy rescues midbrain dopamine neurons from α-synuclein toxicity. Proc. Natl. Acad. Sci. U.S.A. 110, E1817-E1826
67. Xilouri, M., Brekk, O. R., Landeck, N., Pitychoutis, P. M., Papasilekas, T., Papadopoulou-Daifoti, Z., Kirik, D., and Stefanis, L. (2013) Boosting chaperone-mediated autophagy in vivo mitigates α-synuclein-induced neurodegeneration. Brain 136, 2130-2146
68. Xilouri, M., Vogiatzi, T., Vekrellis, K., Park, D., Stefanis, L. (2009) Abberant α-Synuclein confers toxicity to neurons in part through inhibition of chaperone-mediated autophagy. PLoS ONE 4, e5515
69. Jameson, D. M., Croney, J. C., and Moens, P. D. (2003) Fluorescence: basic concepts, practical aspects, and some anecdotes. Methods Enzymol. 360, 1-43
70. Chambraud, B., Sardin, E., Giustiniani, J., Dounane, O., Schumacher, M., Goedert, M., and Baulieu, E. E. (2010) A role for FKBP52 in Tau protein function. Proc. Natl. Acad. Sci. U.S.A. 107, 2658-2663
71. Ulrich, E. L., Akutsu, H., Doreleijers, J. F., Harano, Y., Ioannidis, Y. E., Lin, J., Livny, M., Mading, S., Maziuk, D., Miller, Z., Nakatani, E., Schulte, C. F., Tolmie, D. E., Kent Wenger, R., Yao, H., and Markley J. L. (2008) BioMagResBank. Nucleic Acids Res. 36, D402-D408